



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



BZAD-01

Item No. 38788

CAS Registry No.: 305339-41-7
Formal Name: 4-(trifluoromethoxy)-N-[[2-(trifluoromethyl)phenyl]methyl]-benzenecarboximidamide
MF: C₁₆H₁₂F₆N₂O
FW: 362.3
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BZAD-01 is supplied as a solid. A stock solution may be made by dissolving the BZAD-01 in the solvent of choice, which should be purged with an inert gas. BZAD-01 is soluble in methanol.

Description

BZAD-01 is an antagonist of NR2B subunit-containing NMDA receptors ($K_i = 72 \text{ nM}$).¹ It is selective for NR2B subunit-containing NMDA receptors over those containing NR2A subunits in a calcium mobilization assay (IC_{50} s = 47 and >10,000 nM, respectively). Oral administration of BZAD-01 reduces hyperalgesia induced by carrageenan in rats ($ED_{50} = 5.5 \text{ mg/kg}$). BZAD-01 (10 mg/kg) reduces dopaminergic neuron loss in the rat substantia nigra pars compacta and improves measures of ipsilateral curling, ipsilateral head positioning, and beam walking in a rat model of Parkinson's disease induced by the catecholaminergic neurotoxin 6-OHDA (Item No. 25330).²

References

1. Claiborne, C.F., McCauley, J.A., Libby, B.E., *et al.* Orally efficacious NR2B-selective NMDA receptor antagonists. *Bioorg. Med. Chem. Lett.* **13**(4), 697-700 (2003).
2. Leaver, K.R., Allbutt, H.N., Creber, N.J., *et al.* Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease. *Clin. Exp. Pharmacol. Physiol.* **35**(11), 1388-1394 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/15/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM